SG/CALL/ASTRAZENECA/10000/0.1/20.09.24 | Delayed Deutsche Boerse AG 12:45:05 2024-06-17 pm EDT | ||
| 2.91 EUR | -3.96% |
|
| Current month | +12.64% | ||
| 1 month | +7.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 2.91 | -3.96% |
| 24-06-14 | 3.03 | +5.57% |
| 24-06-13 | 2.87 | -1.71% |
| 24-06-12 | 2.92 | +1.74% |
| 24-06-11 | 2.87 | -8.31% |
Delayed Quote Deutsche Boerse AG
Last update June 17, 2024 at 12:45 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU13YB |
| ISIN | DE000SU13YB6 |
| Date issued | 2023-11-13 |
| Strike | 10,000 p |
| Maturity | 2024-09-20 (95 Days) |
| Parity | 10 : 1 |
| Emission price | 1.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.28 € |
|---|---|
| Lowest since issue | 0.54 € |
| Spread | 0.25 € |
| Spread % | 7.89% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
174.4
USD
Spread / Average Target
+9.95%
- Stock Market
- Warrants
- Warrant
